ES2324538T3 - Anticuerpos anti-hsp terapeuticos y de diagnostico. - Google Patents

Anticuerpos anti-hsp terapeuticos y de diagnostico. Download PDF

Info

Publication number
ES2324538T3
ES2324538T3 ES04803556T ES04803556T ES2324538T3 ES 2324538 T3 ES2324538 T3 ES 2324538T3 ES 04803556 T ES04803556 T ES 04803556T ES 04803556 T ES04803556 T ES 04803556T ES 2324538 T3 ES2324538 T3 ES 2324538T3
Authority
ES
Spain
Prior art keywords
antibody
cells
hsp70
antibodies
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES04803556T
Other languages
English (en)
Spanish (es)
Inventor
Gabriele Multhoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Multimmune GmbH
Original Assignee
Multimmune GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34639281&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2324538(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Multimmune GmbH filed Critical Multimmune GmbH
Application granted granted Critical
Publication of ES2324538T3 publication Critical patent/ES2324538T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES04803556T 2003-12-05 2004-12-06 Anticuerpos anti-hsp terapeuticos y de diagnostico. Active ES2324538T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03028144 2003-12-05
EP03028144 2003-12-05

Publications (1)

Publication Number Publication Date
ES2324538T3 true ES2324538T3 (es) 2009-08-10

Family

ID=34639281

Family Applications (2)

Application Number Title Priority Date Filing Date
ES04803556T Active ES2324538T3 (es) 2003-12-05 2004-12-06 Anticuerpos anti-hsp terapeuticos y de diagnostico.
ES09003983.5T Active ES2484340T3 (es) 2003-12-05 2004-12-06 Anticuerpos anti hsp70 terapéuticos y diagnósticos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES09003983.5T Active ES2484340T3 (es) 2003-12-05 2004-12-06 Anticuerpos anti hsp70 terapéuticos y diagnósticos

Country Status (8)

Country Link
US (3) US7700737B2 (de)
EP (2) EP2070947B1 (de)
JP (2) JP4898452B2 (de)
AT (1) ATE426617T1 (de)
CY (2) CY1109125T1 (de)
DE (1) DE602004020266D1 (de)
ES (2) ES2324538T3 (de)
WO (1) WO2005054295A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005054295A2 (en) * 2003-12-05 2005-06-16 Multimmune Gmbh Therapeutic and diagnostic anti-hsp 70 antibodies
CA2626238C (en) 2005-10-17 2015-10-06 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
PT2484371E (pt) 2008-06-26 2015-03-03 Orphazyme Aps Uso da hsp70 como um regulador da atividade enzimática
WO2011154908A1 (en) * 2010-06-08 2011-12-15 National University Of Ireland, Galway Manipulation of hsp70 and ire1alpha protein interactions
ES2753169T3 (es) 2010-11-30 2020-04-07 Orphazyme As Procedimientos para aumentar la actividad intracelular de Hsp70
AU2013207669C1 (en) 2012-01-13 2018-05-31 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
JP6486278B2 (ja) 2013-01-15 2019-03-20 メモリアル スローン ケタリング キャンサー センター 免疫原性ｗｔ−１ペプチドおよびその使用法
BR112017004948A2 (pt) 2014-09-15 2017-12-05 Orphazyme Aps formulação farmacêutica.
KR102329836B1 (ko) 2015-01-26 2021-11-19 셀렉티스 암 면역치료를 위한 항-CLL1 특이적 단일-체인 키메라 항원 수용체들(scCARS)
WO2016120325A1 (en) 2015-01-27 2016-08-04 Klinikum Rechts Der Isar Der Technischen Universität München Quantitative assay for heat shock protein 70 (hsp70) protein in body fluids
CN108883934A (zh) * 2016-02-02 2018-11-23 M技术株式会社 微粒分散液的精密改性方法
EP3442530A1 (de) 2016-04-13 2019-02-20 Orphazyme A/S Hitzeschockproteinen und cholesterinhomöostase
RU2750154C2 (ru) 2016-04-29 2021-06-22 Орфазим А/С Аримокломол для лечения ассоциированных с глюкоцереброзидазой нарушений
EP3675877A1 (de) 2017-08-31 2020-07-08 Multimmune GmbH Hsp70-basierte kombinationstherapie
US20230128075A1 (en) * 2020-03-27 2023-04-27 Board Of Regents, The University Of Texas System Monoclonal antibodies targeting hsp70 and therapeutic uses thereof
CA3202568A1 (en) 2020-11-19 2022-05-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof
WO2023056361A1 (en) * 2021-09-29 2023-04-06 Board Of Regents, The University Of Texas System Anti-hsp70 antibodies and therapeutic uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP1690934A3 (de) 1990-01-12 2008-07-30 Abgenix, Inc. Bildung von xenogenen Antikörpern
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
JP2702285B2 (ja) 1992-08-21 1998-01-21 バイオジェン，インコーポレイテッド Ｔａｔ由来の輸送ポリペプチド
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
WO1994029469A2 (en) 1993-06-07 1994-12-22 Vical Incorporated Plasmids suitable for gene therapy
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU723325B2 (en) 1995-06-23 2000-08-24 President And Fellows Of Harvard College Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
WO1999059633A1 (en) 1998-05-20 1999-11-25 Immunomedics, Inc. Therapeutics using a bispecific anti-hla class ii invariant chain x anti-pathogen antibody
US20040180046A1 (en) 2000-04-26 2004-09-16 Jeff Himawan Bispecific molecules and uses thereof
ES2326114T3 (es) * 2000-09-13 2009-10-01 Multimmune Gmbh Un peptido de hsp70 estimulador de la actividad de las celulas asesinas naturales (nk) y los usos del mismo.
WO2003086383A1 (en) * 2002-04-12 2003-10-23 Multimmune Gmbh Non-toxic amounts of protein-aggregating substances stimulate hsp70 expression and function as anti-tumor agents
EP1695093A1 (de) * 2003-12-05 2006-08-30 multimmune GmbH Verbindungen und verfahren zur behandlung und diagnose von neoplastischen und infektiösen krankheiten
WO2005054295A2 (en) * 2003-12-05 2005-06-16 Multimmune Gmbh Therapeutic and diagnostic anti-hsp 70 antibodies

Also Published As

Publication number Publication date
CY1116052T1 (el) 2017-02-08
WO2005054295A3 (en) 2006-12-28
JP4898452B2 (ja) 2012-03-14
US8440188B2 (en) 2013-05-14
ATE426617T1 (de) 2009-04-15
US7700737B2 (en) 2010-04-20
WO2005054295A2 (en) 2005-06-16
EP1706423A2 (de) 2006-10-04
EP1706423B1 (de) 2009-03-25
CY1109125T1 (el) 2014-07-02
JP2008502314A (ja) 2008-01-31
JP2012006933A (ja) 2012-01-12
WO2005054295A8 (en) 2005-08-18
ES2484340T3 (es) 2014-08-11
DE602004020266D1 (de) 2009-05-07
US20070231337A1 (en) 2007-10-04
EP2070947A1 (de) 2009-06-17
US20100143356A1 (en) 2010-06-10
US20120087931A1 (en) 2012-04-12
JP5414750B2 (ja) 2014-02-12
EP1706423B8 (de) 2009-07-08
EP2070947B1 (de) 2014-06-11

Similar Documents

Publication Publication Date Title
ES2324538T3 (es) Anticuerpos anti-hsp terapeuticos y de diagnostico.
ES2924722T3 (es) Unión de inmunofusión de scFv biespecífico (BIf) a CD123 y CD3
ES2523502T3 (es) Anticuerpos anti-CD33 y su aplicación para el inmunotargeting en el tratamiento de enfermedades asociadas a CD33
ES2889906T3 (es) Proteínas de unión triespecíficas y usos médicos
JP7333104B2 (ja) Ｂ７－ｈ３に対するモノクローナル抗体および細胞治療におけるその使用
ES2203141T3 (es) Polipeptidos cd19 x cd3 especificos y su utilizacion.
ES2711377T3 (es) Molécula Fv de unión a antígenos multivalente
ES2283368T3 (es) Anticuerpos biespecificos anti-cd19 y anti-cd16 y usos de los mismos.
RU2355705C2 (ru) Одноцепочечное цикличное триспецифическое антитело
ES2337237T3 (es) Anticuerpo biespecifico anti-cancer de ovario humano-anti-cd3.
ES2764805T3 (es) Terapia de combinación que comprende una inmunocitocina inflamatoria y una célula T con receptor de antígeno quimérico (CAR)
ES2881575T3 (es) Moléculas de unión, especialmente anticuerpos, que se unen a L1CAM (CD171)
CN102250245B (zh) 抗b细胞淋巴瘤的双特异性抗体及其用途
ES2954851T3 (es) Proteínas de unión multiespecífica que se unen a HER2, NKG2D y CD16, y métodos de uso
BR112014001573B1 (pt) Molécula fv ao antígeno multivalente
WO2022057871A1 (zh) 抗4-1bb-抗pd-l1双特异性抗体、其药物组合物及用途
US20230340119A1 (en) Composition of triax antibodies and method of making and using thereof
JP2023525778A (ja) 抗ｂｃｍａ抗体およびキメラ抗原受容体
US20230181640A1 (en) Anti-bcma antibodies and chimeric antigen receptors
WO2022151960A1 (zh) B7-h3嵌合抗原受体修饰的t细胞及其应用
WO2021031736A1 (zh) 多功能抗体、其制备及其用途
Nadal Isolation and validation of novel monoclonal antibodies targeting the tumor microenvironment for the selective delivery of cytokines payloads
JP2022541504A (ja) がん治療のためのインテグリン標的化ノッティン－ｆｃ融合体と抗ｃｄ４７抗体の併用
EP1534754A2 (de) Bispezifische antigenbindende zusammensetzungen und damit in zusammenhang stehende verfahren